s6y

Elicio Therapeutics, Inc.

Ticker
ELTX
CIK
1601485
Industry
Pharmaceutical Preparations
Formerly
Angion Biomedica Corp.

Financials 27

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K/A Annual Report for period ending Dec 31, 2025
  5. 10-K Annual Report for period ending Dec 31, 2025
  6. 10-Q Quarterly Report for period ending Sep 30, 2025
  7. 10-Q Quarterly Report for period ending Jun 30, 2025
  8. 10-Q Quarterly Report for period ending Mar 31, 2025
  9. 10-K Annual Report for period ending Dec 31, 2024
  10. 10-Q Quarterly Report for period ending Sep 30, 2024

All 27 financials filings

News 82

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 82 news filings

Ownership 160

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 160 ownership filings

Prospectus 51

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  3. S-3/A Registration statement for specified transactions by certain issuers
  4. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  5. S-3/A Registration statement for specified transactions by certain issuers
  6. S-3 Registration statement for specified transactions by certain issuers
  7. S-3 Registration statement for specified transactions by certain issuers
  8. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  9. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  10. 424B3 Prospectus filed pursuant to Rule 424(b)(3)

All 51 prospectus filings

Proxies 6

  1. DEF 14A Definitive proxy statements
  2. DEF 14A Definitive proxy statements
  3. DEF 14A Definitive proxy statements
  4. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEF 14A Definitive proxy statements

Other 59

  1. SCHEDULE 13G
  2. SCHEDULE 13G/A
  3. EFFECT Notice of Effectiveness
  4. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  5. UPLOAD Letter (PDF)
  6. EFFECT Notice of Effectiveness
  7. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  8. SCHEDULE 13G/A
  9. SCHEDULE 13D/A
  10. SCHEDULE 13G/A

All 59 other filings